Cure-Related Research Resources
A resource listing of articles, reports, websites, and ongoing clinical trials related to the research effort to cure HIV infection.
An Activist’s Guide to the LAM Test
Tuberculosis (TB) is the number one killer of people living with HIV/AIDS, causing one in three of all AIDS-related deaths. People living with HIV are at increased risk of developing TB, and of dying from it—especially when they have advanced…
Statement from the ACT NOW:END AIDS Coalition on President Trump’s State of the Union Commitment to Eradicate AIDS
The ACT NOW:END AIDS Coalition, of which TAG is a founding member, released this statement today calling for the administration’s efforts to end the HIV epidemic to be rooted in fact, science, and sensible policies that are consistent with the stated goal of ending HIV.
Treatment Action Group Statement on the HVTN 702 HIV Vaccine Trial Results
Treatment Action Group acknowledges with profound disappointment today’s announcement that the HIV Vaccine Trials Network HVTN 702 study did not demonstrate efficacy in preventing HIV acquisition.
Good COPs or Bad COPs: Promoting Interventions for Coinfections and AIDS in 2020 PEPFAR Country Operational Plans (COPs)
On January 22, 2020, Treatment Action Group (TAG), Médecins Sans Frontières (MSF) Access Campaign, Health GAP, IMPAACT4TB, and AVAC presented this webinar on how to engage in PEPFAR COPs advocacy. Materials are online now.
Treatment Action Group Applauds Progress on Ending HIV in New York, Cautions Against Complacency
Treatment Action Group (TAG) applauds progress in New York towards ending HIV as an epidemic, with record decreases in estimated statewide and citywide HIV incidence in 2018. TAG states that accelerating impact at the community level will be critical to reach the Ending the Epidemic 2020 targets.
Clinical Trials for People with Suboptimal Immune Reconstitution Despite HIV Suppression
Some individuals who initiate antiretroviral therapy (ART) experience limited recovery of CD4 T cell numbers despite suppression of HIV viral load to undetectable levels. The most common risk factors for this type of discordant response to ART are low CD4 T cell count at the time of starting and older age.
TAG Welcomes HHS Lawsuit Against Gilead; Urges Dramatic Scale-Up of Low-Cost PrEP
Treatment Action Group (TAG) welcomes the U.S. Department of Health and Human Services (HHS) pursuit of a lawsuit against Gilead Sciences, Inc., the manufacturer of Truvada and Descovy, the only two FDA-approved pills for pre-exposure prophlyaxis (PrEP) to prevent HIV.
Story: American Gene Technologies HIV Gene Therapy
November 2019 Examples of media coverage: Gene Tech Company Claims to Have Found a Cure for HIV/AIDS – NewNowNext, November 8, 2019 Researchers believe they’ve found the cure for HIV/AIDS – Pink News, November 8, 2019 Research Lab Believes They Have HIV/AIDS Cure – Instinct Magazine,…
A Landscape Analysis of HIV Cure-Related Clinical Trials in 2018
In August 2018, the Bill & Melinda Gates Foundation contracted TAG to undertake a survey of investigators conducting studies included in our “Research Toward a Cure” clinical trials listing, in order to obtain more detailed information about the current landscape of HIV cure-related clinical research.